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The combination of all-trans retinoic acid (ATRA) and primaquine (PMQ) has been shown to be effective for therapy of Pneu-
mocystis pneumonia (PCP). Since a high concentration of ATRA has significant adverse effects, the possibility that vitamin D can
be used to replace ATRA for PCP therapy was investigated. C57BL/6 mice were immunosuppressed by depleting CD4 cells and
infected with Pneumocystis murina 1 week after initiation of immunosuppression. Three weeks after infection, the mice were
treated orally for 3 weeks with vitamin D3 (VitD3) alone, PMQ alone, a combination of VitD3 and PMQ (VitD3-PMQ), or a com-
bination of trimethoprim and sulfamethoxazole (TMP-SMX). Results showed that VitD3 (300 IU/kg/day) had a synergistic effect
with PMQ (5mg/kg/day) for therapy of PCP. Flow cytometric studies showed that this VitD3-PMQ combination recovered the
CD11blow CD11chigh alveolar macrophage population in mice with PCP as effectively as TMP-SMX. The VitD3-PMQ combina-
tion also reduced the massive infiltration of inflammatory cells into the lungs and the severity of lung damage. VitD3 was also
shown to reduce the dose of TMP-SMX required for effective treatment of PCP. Taken together, results of this study suggest that
a VitD3-PMQ combination can be used as an alternative therapy for PCP.
Pneumocystis jirovecii is the causative organism of Pneumocystispneumonia (PCP), which is a common opportunistic disease
in patients with AIDS. According to the 2014 CDC statistics, the
incidence of PCP in the United States is 9% among hospitalized
AIDS patients and 1% among solid organ transplant recipients
(1). The mortality rate of PCP ranges from 5% to 40% in patients
with treatment and approaches 100% in those without treatment
(1). Pneumocystis organisms are also found in other mammalian
species, and those found in mice are called P. murina. P. carinii
refers to the major form of Pneumocystis found in rats. Although
Pneumocystis organisms are classified as fungi, they are not sus-
ceptible to most antifungal drugs. Currently, the most effective
regimen for PCP therapy is the combination of trimethoprim and
sulfamethoxazole (TMP-SMX). However, approximately 10% of
people are allergic to sulfa drugs (2), and many AIDS patients fail
therapy with TMP-SMX (3). In addition, TMP-SMX may cause
adverse effects, such as rash, fever, neutropenia, thrombocytope-
nia, or transaminase elevation (3).
In PCP, alveolar macrophages (AMs) are defective in phago-
cytosis and reduced in number (4). We have found that the ex-
pression of the PU.1 gene in AMs is decreased during PCP (5).
This PU.1 downregulation may be a cause of AM dysfunction
because PU.1 regulates the expression ofmanymacrophage recep-
tors (5–9). Since PU.1 also regulates the differentiation of mono-
cytes into AMs (10), its decrease in expression would adversely
affect this process, resulting in a decreased number of AMs during
PCP. We have also found that myeloid-derived suppressor cells
(MDSCs) accumulate in the lungs of mice and rats with PCP (11).
The number of these cells increases as Pneumocystis infection be-
comes more severe and decreases with successful TMP-SMX
treatment, suggesting that Pneumocystis infection causes MDSC
accumulation. Surprisingly, treatment of Pneumocystis-infected
mice and rats with all-trans retinoic acid (ATRA), a metabolite of
vitamin A, for 5 weeks was found to clear the infection, with the
disappearance of MDSCs in their lungs (11). These findings sug-
gest that MDSCs are incompletely differentiated monocytes and
that ATRA treatment stimulates them to differentiate into AMs,
allowing the host to defend the infection.
We have also found that ATRA (5 mg/kg of body weight/day)
in combination with primaquine (PMQ) (2 mg/kg/day) is as ef-
fective as TMP-SMX for PCP therapy and clears the infection in 2
weeks (12). Because ATRA has significant adverse effects (13), we
tested whether ATRA can be replaced with vitamin D, as it has
been shown to stimulate MDSCs to differentiate into antigen-
presenting cells (14, 15). Vitamin D is synthesized in the skin by
first converting 7-dehydrocholesterol (provitamin D3) to
precholecalciferol (previtamin D3) upon exposure to sunlight. At
body temperature, precholecalciferol is converted to cholecalcif-
erol, which is vitamin D3 (VitD3). Another source of vitamin D is
food, such as eggs and fatty fish. Vitamin D is measured in inter-
national units (IU) (25 ng/IU) in nutritional supplements and in
nanograms per milliliter or nanomoles per liter in serum or
plasma (1 nmol/liter 0.4006 ng/ml). Once produced in the skin
or absorbed from the gut, vitaminD is carried by vitaminD-bind-
ing protein and transported to the liver, where it is metabolized to
25-hydroxyvitamin D3 [25(OH)D3] (also called calcidiol) by 25-
hydroxylase (CYP2R1). 25-Hydroxyvitamin D3 is then converted
in the kidney by 25-OH-D3-1-hydroxylase (CYP27B1) to 1,25-
dihydroxyvitamin D3 [1,25(OH)2D3] (also called calcitriol),
which is the active form of vitaminD. Results of this study showed
that vitamin D3 (VitD3) supplementation decreased the severity
of Pneumocystis infection. Furthermore, VitD3 was found to have
a synergistic effect with PMQ for PCP therapy.
MATERIALS AND METHODS
Mouse model of PCP. C57BL/6 mice were obtained fromHarlan (India-
napolis, IN). All mice used in this study were female, 18 to 20 g in weight.
The study was approved by the Indiana University Animal Care and Use
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Committee and carried out under the supervision of veterinarians. For
immunosuppression, each mouse was injected intraperitoneally with 0.3
mg anti-L3T4 monoclonal antibody (MAb) (clone GK1.5; Harlan, India-
napolis, IN) once a week to deplete CD4 cells for the entire period of the
study. Thismethod of immunosuppression has been shown to be effective
(16) and has been used inmany PCP studies (5, 11, 12, 17). Oneweek after
the initial injection of the antibody, each immunosuppressed mouse was
transtracheally inoculated with 2  106 P. murina organisms in 30 l
phosphate-buffered saline (PBS). The Pneumocystis organisms used as
inoculum were obtained from heavily infected lungs and isolated as pre-
viously described (4). Mice were given drinking water containing tetracy-
cline (0.74 g/liter) to prevent bacterial infections as previously described
(5, 11, 12).
Drug treatment. The following regimens were used: TMP-SMX
(TMP, 50 mg/kg/day; SMX, 250 mg/kg/day), ATRA-PMQ (ATRA, 5 mg/
kg/day in 8% dimethyl sulfoxide [DMSO]; PMQ, 2 mg/kg/day in water),
VitD3 (300 IU/kg/day in 8% DMSO), PMQ (5 mg/kg/day), VitD3-PMQ
(VitD3, 300 IU/kg/day; PMQ, 5 mg/kg/day). VitD3 was used at 300 IU/
kg/day, as our preliminary studies showed no difference in efficacy be-
tween this dose and 3,000 IU/kg/day (data not shown). All drugs were
given orally by gavage. Five mice in each group were sacrificed for inves-
tigation of drug effects at a specific time point. TMP-SMX (Septra), in
liquid form, was purchased from Hi-Tech Pharmacal (Amityville, NY).
ATRA, VitD3 (cholecalciferol), and PMQ were obtained from Sigma-
Aldrich (St. Louis, MO).
Evaluation of Pneumocystis infection.Mice were anesthetized by in-
tramuscular injection of ketamine cocktail (ketamine hydrochloride, 90
mg/kg; acepromazine, 1.5 mg/kg; xylazine, 2.5 mg/kg) and then sacrificed
by cardiac exsanguination. The lungs of the mice in each group were
removed, fixed with buffered 10% formalin overnight, and then embed-
ded in paraffin as described previously (11). Five-micrometer histologic
sections were stained with hematoxylin and eosin (H&E) to evaluate lung
inflammation and with Grocott’s methenamine silver (GMS) to assess
organism load by microscopy.
BAL. Lungs were lavagedwith sterile saline (1ml at a time) through an
intratracheal catheter until a total of 10ml of lavage fluid was recovered as
described previously (18). The bronchoalveolar lavage fluid (BALF) was
centrifuged at 300  g for 10 min to pellet BAL cells. The pelleted cells
were washed twice with PBS and then resuspended in 1 ml PBS.
Flow cytometry of BAL cells. BAL cells were incubated with 5% bo-
vine serumalbumin for 1 h and then reactedwith anti-mouse phycoeryth-
rin (PE)-labeled anti-CD11b (catalog no. 101207; BioLegend) and Alexa
Fluor 647-labeled anti-CD11c (catalog no. 117314; BioLegend) antibod-
ies on ice for 1 h. Control cells were stained with PE- or fluorescein iso-
thiocyanate (FITC)-labeled isotype IgG. The antibody-stained cells were
washed with 4 ml PBS and then examined with a BD FACSCalibur flow
cytometer (BDBiosciences) as described previously (11). FlowJo software
(Tree Star, Ashland, OR) was used to analyze the flow cytometry data.
Determination of albumin andLDH levels inBALF.The first 1ml of
BALF was used for determination of albumin and lactate dehydroge-
nase (LDH) levels. The albumin concentration was measured using a
QuantiChrom BCG albumin assay kit (BioAssay Systems, Hayward,
CA), and LDH levels were determined using an LDH cytotoxicity assay
kit (Cayman Chemical, Ann Arbor, MI), according to the manufactur-
ers’ instructions.
Measurement of vitamin D3 and calcium levels in mouse serum.
Mouse blood was collected by cardiac puncture and then placed in a 37°C
incubator for 30 min. After centrifugation of the clotted blood for 15 min
at 1,500  g at 4°C, the clarified serum was transferred to a new tube.
Serum VitD3 levels were determined by liquid chromatography-tandem
mass spectrometry (LC-MS/MS) as described previously (19). Control
25(OH)D3 and deuterated vitamin D [d6-25(OH)D] were purchased
from Cerilliant (Round Rock, TX). LC/MS-grade acetonitrile, methanol,
and formic acid were purchased from Fisher Scientific (Fair Lawn, NJ).
The internal standard consisted of a stock solution of 5 g/ml of d6-
25(OH)D inmethanol diluted with acetonitrile to a final concentration of
75 ng/ml.
A total of seven 25(OH)D3 calibration standards with final concentra-
tions of 0 to 150 ng/ml in 50% methanol were prepared. To measure
VitD3 levels in serum, 200 l of precipitating reagent (acetonitrile) with
internal standard [d6-25(OH)D] was added to 100 l of mouse serum
samples, control samples, and calibrator samples. After vortexing for 30 s,
samples were centrifuged at 4,000  g for 10 min to pellet the insoluble
substances. The supernatant of each sample was transferred to an au-
tosampler vial and sealed.
Solvent delivery and sample introduction were performed using a
ThermoScientific ARIA/Transcend TLX2 LC system with pumps and
ThermoScientific (San Jose, CA) high-performance liquid chromatogra-
phy (HPLC) columns. After injection (50 l) at room temperature, addi-
tional online sample preparationwas performedusing aTurboFlowC18-P
XL column (50 by 0.5 mm). Chromatographic separation of VitD3 from
other substances was performed on an Accucore C18 column (50 by 3
mm) at room temperature. Detection of VitD3 was performed on a TSQ
Vantage triple-quadrupole mass spectrometer (ThermoScientific, San
Jose, CA). Quantitation of VitD3 was performed using TraceFinder 3.0
version 3.0.742.16 software (ThermoScientific) by a comparison with the
standard curve derived from the seven 25(OH)D3 calibration standards.
The total calcium measurement was based on the observation that
a purple Ca-arsenazo III complex is formed when calcium ion is re-
acted with arsenazo III (2,2=-[1,8-dihydroxy-3,6-disulfonaphthylene-
2,7-bisazo]-bisbenzenear-sonic acid) (20). For each measurement, 2.5
l of serum was mixed with 21 l of arsenazo III and diluted with 150
l of water (OSR65117; Beckman-Coulter) on a Beckman-Coulter
(Brea, CA) AU680 analyzer. The resulting Ca-arsenazo III complex
was quantified spectrophotometrically at 660 nm.
Statistic analysis. An unpaired two-tail Student t test was performed
to compare the difference between treatment and control (untreated)
groups or the efficacy ofVitD3-PMQto that of TMP-SMX, PMQalone, or
VitD3 alone in PCP therapy. The data presented are means  standard
deviations (SD). A P value of0.05 is considered significant.
RESULTS
Effective treatment of PCP by a combination of VitD3-PMQ.
Experiments were first performed to investigate whether VitD3
can replace ATRA and whether it has any synergistic effect with
PMQ for PCP therapy. Mice were infected with Pneumocystis 1
week after initiation of immunosuppression. The infected mice
(referred to here as PCPmice) were treated with a combination of
VitD3 (300 IU/kg/day) and PMQ (2 mg/kg/day), starting at 3
weeks after infection. Control PCPmice were treated with ATRA-
PMQ (ATRA, 5 mg/kg/day; PMQ, 2 mg/kg/day) or TMP-SMX as
previously described (12). Results showed that this combination
of VitD3 and PMQ was not as effective as the ATRA-PMQ com-
bination and did not completely clear Pneumocystis infection after
3weeks of treatment. Therefore, the dose of PMQwas increased to
5 mg/kg/day and used in combination with 300 IU/kg/day of
VitD3. To evaluate the efficacy of this new VitD3-PMQ regimen,
the gross lung morphology was first examined. Untreated PCP
mice were found to have greatly enlarged lungs. No significant
enlargement of lungs was observed in PCP mice treated with
TMP-SMX, ATRA-PMQ, PMQ alone (5 mg/kg/day), or VitD3-
PMQ (Fig. 1). These results suggest that the combination of VitD3
at 300 IU/kg/day and PMQ at 5 mg/kg/day is effective for treat-
ment of PCP. This VitD3 and PMQ combination (referred to here
as VitD3-PMQ) was used for all subsequent studies.
Reduction in lung inflammation by VitD3-PMQ treatment.
To confirm the therapeutic effect of VitD3-PMQ, lung sections of
uninfected, untreated PCPmice and PCPmice treated with TMP-
Lei et al.
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SMX, PMQ alone, VitD3-PMQ, or VitD3 alone were examined.
Hematoxylin and eosin (H&E) staining of the lung sections
showed the typical severe inflammation and foamy exudates in the
lungs of untreated PCPmice after 6weeks of infection. TMP-SMX
or PMQ treatment of PCP mice for 3 weeks (starting at 3 weeks
after infection) greatly reduced the severity of inflammation, but
mild inflammation was still present (Fig. 2A). Treatment of PCP
mice with VitD3-PMQ for 3 weeks reduced the severity of inflam-
mation much more than that with PMQ alone and almost com-
pletely eliminated inflammatory cells. No or minimal foamy exu-
dates were seen in PCPmice treated with TMP-SMZ, PMQ alone,
or VitD3-PMQ. In those treated with VitD3 alone for 3 weeks, no
significant inflammatory infiltrate was observed, despite the pres-
ence of enormous amounts of foamy exudates in alveoli (Fig. 2A).
Methenamine silver staining revealed numerous Pneumocystis or-
ganisms in the lung sections of untreated PCPmice but no organ-
isms in those of TMP-SMX-, PMQ-, or VitD3-PMQ-treated PCP
mice. The organism load in the lung sections of PCP mice treated
withVitD3 alonewasmuch lower than that of untreatedPCPmice
(Fig. 2B). In addition, mice treated with VitD3-PMQ were more
physically active and gained more weight each week than did the
mice in any other group. The mean weight gain per week for
uninfected mice was 0.56 g, and that for untreated PCP mice was
0.29 g (P  0.026, compared to untreated group). TMP-SMX-
FIG 1 Gross lung morphology. Immunosuppressed mice were infected with
Pneumocystis for 3 weeks and then treated with the following regimens for 3
weeks: TMP-SMX, ATRA-PMQ (5mg ATRA/kg/day and 2mg PMQ/kg/day),
PMQ (5 mg/kg/day), or VitD3-PMQ (300 IU VitD3/kg/day and 5 mg PMQ/
kg/day). Representative images of lungs from various groups of mice are
shown. Controls are lungs from uninfected mice and untreated PCP mice.
FIG 2 Lung histopathology. The following groups of mice were investigated: uninfected, untreated PCPmice, and PCPmice treated with TMP-SMX, PMQ, or
VitD3-PMQ for 3 weeks. (A) Representative H&E-stained lung sections. Arrows indicate infiltrated inflammatory cells. (B) Lung sections stained with Grocott’s
methenamine silver. Pneumocystis cysts are seen as black dots or clusters.
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treated PCP mice gained an average of 0.74 g (P 0.005, com-
pared to untreated group), and those treated with PMQ alone
gained 0.47 g per week. Surprisingly, VitD3-PMQ-treated PCP
mice gained an average of 0.84 g per week (P  0.007, com-
pared to untreated group), 0.28 g higher than that in unin-
fected mice. (Fig. 3).
RecoveryofAMsbyVitD3-PMQtreatment.Todetermine the
effect of various treatments on the number of AMs, flow cytomet-
ric examinations of BAL cells were performed using PE-labeled
anti-CD11b and Alexa Fluor 647-labeled anti-CD11c antibodies.
Results showed that the CD11blow CD11chigh AM populations in
uninfected immunosuppressed mice were 91.2%, 82.5%, and
86.2% of total BAL cells at 5, 6, and 7 weeks, respectively, after
initiation of immunosuppression. In untreated PCP mice, this
population of cells was decreased to 32% at 4 weeks, 11.3% at 5
weeks, and 1.95% at 6 weeks after infection. In TMP-SMX-treated
mice, the CD11blow CD11chigh AM population was 66.9% after 1
week of treatment and increased to 73.2% at 2 weeks and 80.5% at
3 weeks after treatment. This population of cells was 42.2% after 1
week and increased to 57.5%after 2weeks and 74.8%after 3weeks
of PMQ treatment. In VitD3-PMQ-treated PCP mice, the
CD11blow CD11chigh AM population was 71% at 1 week, 87.7% at
2 weeks, and 89.2% at 3 weeks after treatment. The most striking
features in mice with PCP were the gradual loss of the CD11blow
CD11chigh AM population and the increase of the CD11bhigh
CD11clow MDSC population. Pneumocystis-infected mice treated
with TMP-SMX, PMQ, or VitD3-PMQ for 3 weeks recovered the
CD11blow CD11chigh AM population to levels close to those of
uninfected mice (Fig. 4A and B).
Reductions in albumin andLDH levels byVitD3-PMQtreat-
ment. To evaluate lung injury, the levels of albumin and LDH in
BALF of the following animal groups were determined: unin-
fected mice, untreated PCP mice, and PCP mice treated with
TMP-SMX, PMQ, or VitD3-PMQ for 3 weeks. As shown in Fig.
5A, albumin levels in the first BALF collected from uninfected
mice were 6.39 mg/dl but were greatly elevated (26.22 mg/dl, P
0.007) in those of untreated PCP mice. Treatment of PCP mice
with PMQ alone (7.53 mg/dl) or VitD3-PMQ (8.35 mg/dl) re-
duced BALF albumin to levels similar to those ofmice treatedwith
TMP-SMX (9.3 mg/dl). The levels of LDH in the BALF of un-
treated PCPmice were approximately five times higher than those
of uninfected mice (852.63 U versus 160.8 U, P  0.001).
Treatment of PCPmice with TMP-SMX reduced their BALF LDH
levels to 281.73 U (P  0.003, compared to untreated group),
close to those of uninfected mice. Treatment of PCP mice with
PMQ (323.33 U, P  0.004, compared to untreated group) or
VitD3-PMQ (276.27 U, P  0.003, compared to untreated
group) reduced LDH levels by approximately 70% (Fig. 5B).
No increase in serum calcium levels after VitD3-PMQ treat-
ment. To ensure that oral administration of VitD3 was effective,
serum vitamin D [25(OH)D3] levels of the following groups of
mice were measured: uninfected mice, untreated PCP mice, and
PCP mice treated with TMP-SMX, PMQ, or VitD3-PMQ. At the
time of vitamin D measurement, untreated PCP mice were in-
fected with Pneumocystis for 6 weeks, and Pneumocystis-infected
mice were treated with TMP-SMX, PMQ alone, or VitD3-PMQ
for 3 weeks, starting at 3 weeks after Pneumocystis infection. The
mean serum 25(OH)D3 levels of the various groups were as fol-
lows: uninfected mice, 31.93 ng/ml; untreated PCP mice, 34.75
ng/ml; PCP mice treated with TMP-SMX, 29.6 ng/ml; PCP mice
treated with PMQ, 32.67 ng/ml; and PCP mice treated with
VitD3-PMQ, 113.8 ng/ml (Fig. 6A). To determine whether vita-
min D treatment caused hypercalcemia, calcium concentrations
in the sera of these groups of mice were determined. Results
showed that serum calcium levels in uninfected mice, untreated
PCP mice, and PCP mice treated with TMP-SMX, PMQ, or
VitD3-PMQ were all about the same (9 mg/dl) (Fig. 6B). There-
fore, VitD3 treatment did not raise serum calcium levels, even
though serum 25(OH)D3 levels of treated mice were approxi-
mately 4-fold that of untreated mice.
Reduction in TMP-SMX dose by vitamin D. To determine
whether VitD3 can reduce the dose of TMP-SMX required for
PCP therapy, combinations of VitD3 with full (50 mg TMP plus
250 mg SMX per kg/day) and one-third doses of TMP-SMX were
tested on mice that had been infected with Pneumocystis for 3
weeks. Results showed that VitD3 at 300 IU/kg/day reduced the
dose of TMP-SMX required for effective therapy of PCP. As
shown in Fig. 7A, numerous Pneumocystis cysts are present in
methenamine silver-stained lung sections from PCP mice treated
with one-third dose of TMP-SMX alone at 1, 2, and 3 weeks after
treatment, but few are seen in sections from those treated with the
combination of VitD3 and one-third dose of TMP-SMX even just
1 week of treatment. The combination of VitD3 with one-third
dose of TMP-SMXwas also as effective as a full dose of TMP-SMX
in the control of lung inflammation, as the number of infiltrated
inflammatory cells was greatly decreased after 2 or 3 weeks of
either treatment (Fig. 7B). These results suggest that VitD3 also
has a synergistic effect with TMP-SMX.
DISCUSSION
In this study, we found that VitD3 has a synergistic effect with
PMQ for the treatment of PCP. This property is similar to that of
ATRA, which we have shown to be effective for PCP therapy when
it was used in combination with PMQ (12). However, a higher
dose of PMQ (5 instead of 2 mg/kg/day) was required when it was
used in combination with VitD3 (300 IU/kg/day) for therapy of
PCP. The major therapeutic effect of VitD3 was the reduction of
the infiltration of inflammatory cells into the lungs, as PCP mice
FIG 3 Body weight variation. The body weight of each mouse in the animal
groups described in the legends to Fig. 1 and 2 was determined once a week.
The average weight gain per week of each group of mice is plotted. Data are
presented as means SD of results for 5 mice for each group.
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treated with VitD3-PMQ for 3 weeks had significantly fewer in-
flammatory cells in the lungs than those treated with TMP-SMX
for the same length of time (Fig. 2A). VitD3 treatment also re-
duced the organism burden, even in PCPmice treated with VitD3
alone (Fig. 2B).
As shown in Fig. 4A, the CD11chigh CD11blow AM population
was greatly decreased in untreated PCPmice. Similar to PCPmice
treated with TMP-SMX, PCP mice treated withVitD3-PMQ and
PMQ alone recovered the CD11chigh CD11blow AM population
(Fig. 4A and B). Although TMP-SMX was effective for PCP ther-
apy, it rendered treated animals less active than uninfected mice.
In contrast, mice treated with VitD3-PMQ behaved like unin-
fected ones, with greater weight gain (Fig. 3). This observation
suggests that VitD3-PMQ is less toxic than TMP-SMX. Since sul-
famethoxazole is a component of TMP-SMXandmany people are
allergic to it (2), the use of VitD3-PMQ for therapy of PCP would
avoid this adverse reaction. In addition, VitD3 supplementation
was found to reduce the dose of TMP-SMX required for effective
treatment of PCP by 67% (Fig. 7A and B). As TMP-SMX is cur-
rently the first-line drug for PCP, patients are usually treated with
it as soon as PCP is suspected. A reduced dose of TMP-SMX
would decrease the risk or severity of sulfa drug hypersensitiv-
ity. The cost of the VitD3-PMQ combination is about the same
as that of TMP-SMX.
In addition to suppressing inflammatory responses (21), vi-
tamin D is known to enhance the production of antibacterial
proteins such as cathelicidin and 	-defensin, the formation of
autophagosomes, and the killing of microorganisms by macro-
phages (22). Another possible mechanism of action of vitamin
D is regulation of the expression of its target genes. Vitamin D
works through vitamin D receptor (VDR), which is a nuclear
receptor and is present in many types of cells (23). Vitamin D
has both genomic and nongenomic effects (24). For the genomic
effect, vitamin D binds to nuclear VDR, enabling it to form het-
erodimers with the retinoid-X receptor (RXR). The vitamin D-
VDR-RXR complex acts as a transcription factor and binds to the
FIG4 Flow cytometry of BAL cells. Immunosuppressedmicewere infectedwithPneumocystis and then treatedwithTMP-SMX, PMQ, orVitD3-PMQ.BAL cells
from PCPmice immunosuppressed for 5, 6, and 7 weeks were examined. For treated mice, these three time points correspond to 1, 2, and 3 weeks of treatment.
BAL cells from various groups of mice were stained with PE-labeled anti-CD11b and Alexa Fluor 647-labeled anti-CD11c antibodies and then examined. (A)
Flow cytometry data. The percentage of cells in each quadrant is indicated. (B) Histogram of CD11blow CD11chigh AM populations of various groups of mice.
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vitamin D response element (VDRE), which is present in the pro-
moter region of more than 900 vitamin D-VDR target genes (25).
These genes play major roles in various activities, such as calcium
and phosphate homeostasis, apoptosis, and cell differentiation
(25). For the nongenomic effect, vitamin D binds to VDR located
in caveolae in the plasmamembrane and exerts its effects through
second messengers, such as phospholipase C (PKC), protein ki-
nase C, G protein-coupled receptors, or phosphatidylinositol-3-
kinase (PI3K) (26). Pathways that may be activated by the non-
genomic effects of the vitaminD-VDR complex include those that
are dependent on mitogen-activated protein kinase (27), cyclic
AMP (cAMP) (28), phospholipase A2 (29), phospholipase C (30),
PI3K (31), or protein kinase C (32). It remains to be investigated
whether vitamin D acts through these mechanisms in the supple-
mental PCP therapy.
PMQ is an 8-aminoquinonine. It is normally used in combi-
nation with chloroquine to treat malaria caused by Plasmodium
falciparum (33). A potential adverse effect of PMQ is an increase in
the levels of methemoglobin, in which the ferric ion is replaced by
a ferrous ion. Normally, the methemoglobin level is less than 1%.
A regimen of 15 mg/day PMQ for 14 days has been shown to raise
the methemoglobin level to 5.8% (33). However, a level of less
than 20% methemoglobin is usually asymptomatic. PMQ has
been used at 30 mg daily for a year (34) and 60 mg/kg/day for 7
days without any adverse effects (35). The 5-mg/kg/day dose we
have used in this study in mice is equivalent to 0.3 mg/kg/day (or
18 mg for 60 kg of body weight) in humans, because the effective
dose for mice is approximately 10-fold higher than that for hu-
mans (36). PMQ has been used at 15 to 30 mg per day in combi-
nation with clindamycin (1,800 mg/day) as the second-line drug
for treatment of PCP (37). Another side effect of PMQ is acute
hemolysis in individuals with glucose-6-phosphate dehydroge-
nase (G6PD) deficiency (33). Therefore, the VitD3-PMQ combi-
nation is not recommended for PCP patients with G6PD defi-
ciency.
The replacement of ATRA-PMQ with VitD3-PMQ is a signif-
icant improvement, as ATRA may cause fever, white blood cell
elevation, respiratory distress, interstitial pulmonary infiltrates,
pleural and pericardial effusion, dyspnea, hypotension, or renal
failure (13). It has been shown that a daily uptake of 10,000 IU of
VitD3 is safe in humans (38, 39). The only potential side effect of
high levels of vitaminD is hypercalcemia (
12mg/dl) (40), which
may increase the risk of developing kidney stones. However, this
side effect has been observed only in individuals takingmore than
FIG 5 Albumin and LDH levels in BALF. The first milliliter of BALF collected
was used for the determination of albumin and LDH levels. (A) Albumin levels
in BALF of uninfected mice, untreated PCP mice, and PCP mice treated with
TMP-SMX, PMQ, or VitD3-PMQ for 3 weeks. (B) LDH levels in BALF of the
same animal groups as described for panel A.
FIG 6 Serum 25(OH)D3 and calcium levels. Immunosuppressed mice were
infectedwith Pneumocystis for 4weeks and then treatedwith various regimens.
(A) Serum25(OH)D3 levels in uninfectedmice, untreated PCPmice, and PCP
mice treated with TMP-SMX, PMQ, or VitD3-PMQ for 3 weeks. (B) Total
serum calcium levels of the same animal groups as described for panel A.
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50,000 IU/day with a serum 25(OH)D concentration greater than
700 nmol/liter (280 ng/ml) (39). Therefore, a serum 25(OH)D
level of 600 nmol/liter (240 ng/ml) is considered safe (39).
Without vitamin D supplementation, serum 25(OH)D levels are
in the range of 20 to 50 ng/ml (50 to 125 nmol/liter) in humans
(41–46) and 34 to 50 ng/ml (85 to 125 nmol/liter) in C57BL/6
mice (47). In this study, we found that the mean serum 25(OH)D
level was 31.93 ng/ml in uninfected mice and 34.75 ng/ml in un-
treated PCP mice. Treatment of PCP mice with VitD3-PMQ
raised serum 25(OH)D levels to 113.8 ng/ml (Fig. 6A). Although
this concentration is approximately 4 times higher than that of
untreated mice, no increase in serum calcium levels was observed
(Fig. 6B). There have been attempts to develop 1,25(OH)2D3
analogues without the hypercalcemic side effect. One such exam-
ple is the development of MART-10 [19-nor-2-(3-hydroxypro-
pyl)-1,25-dihydroxyvitamin D3], which does not raise serum
calcium levels (48, 49) and has been shown to be 100-fold more
potent than 1,25(OH)2D3 in inhibiting the growth of several
types of cancer cells in vitro (49–51).
The mode of action of VitD3 supplementation in PCP therapy
is currently unknown and is being investigated. We speculate that
similar to ATRA, VitD3 prevents the formation of MDSCs and
promotes the differentiation of AMs. It is also possible that VitD3
enhances AMs to produce antimicrobial peptides such as catheli-
cidin. These potential actions can increase the self-defense ability
of Pneumocystis-infected hosts. PMQ has been shown to suppress
the proliferation of Pneumocystis organisms (52). The combina-
tion of these two different mechanisms would make the VitD3-
PMQ combination ideal for PCP therapy. It is possible that vita-
min D also has synergistic effects with other drugs, such as
atovaquone and dapsone. These drugs are not used as often as
TMP-SMX because they are less effective (53, 54). However,
they are less toxic than TMP-SMX (54–56). If VitD3 supple-
mentation can also enhance the efficacy of these drugs, we will
have more alternative treatments for PCP patients who cannot
tolerate TMP-SMX.
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